Hydra Biosciences raised $22.2 million in a Series D financing led by MedImmune Ventures, a wholly-owned venture capital fund of MedImmune, the biologics business of the AstraZeneca Group.
Proceeds from the financing will be used to advance multiple Transient Receptor Potential (TRP) ion channel drug programs, with the most advanced program moving toward clinical trials in 2009, to be applied to diseases such as pain, inflammation, and pulmonary disease.
MedImmune Ventures joins existing investors Advanced Technology Ventures, Abingworth, Polaris, BioVenture Investors, Biogen-Idec Ventures, and Lilly Ventures in the Series D round. Hydra Biosciences has raised $47 million in previous rounds of financing.
Hydra Biosciences Raises $22 Million in Series D Financing
(Via Business Wire Health News.)
Theoretically Related Posts
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)
January 16, 2009 at 4:02 pm
[...] your company. John Greathouse, a partner at Rincon Venture Partners, gives an extensive Hydra Biosciences Raises $22 ...